Lv21
130 积分 2023-12-04 加入
P-260: Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX
1个月前
已完结
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
2个月前
已完结
Department of Error
3个月前
已完结
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis
3个月前
已完结
A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China
3个月前
已完结
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
4个月前
已完结
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
5个月前
已完结
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients
5个月前
已完结
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
5个月前
已完结
皖公网安备34019202002308
